Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trientine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatolenticular Degeneration.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 27, 2015
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Aptiv Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trientine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatolenticular Degeneration.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2013
Lead Product(s) : Trientine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Aptiv Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable